MMDA (drug)

MMDA

Systematic (IUPAC) name
1-(7-Methoxy-1,3-benzodioxol-5-yl)-2-propanamine
Clinical data
Legal status	AU: S9 (Prohibited) DE: Anlage I (Controlled) UK: Class A US: Schedule I
Routes of administration	Oral, Insufflation, Rectal
Identifiers
CAS Number	13674-05-0
ATC code	none
PubChem	CID: 26175
ChemSpider	24386
UNII	RG7FY73ZAA Y
Chemical data
Formula	C11H15NO3
Molecular mass	209.24 g/mol
SMILES O1c2cc(cc(OC)c2OC1)CC(N)C

MMDA (3-methoxy-4,5-methylenedioxyamphetamine; 3-methoxy-MDA) is a psychedelic and entactogen drug of the amphetamine class. It is an analogue of lophophine, MDA, and MDMA.

MMDA was described by Alexander Shulgin in his book PiHKAL. Shulgin lists the dosage range of MMDA as 100–250 mg. The first symptoms appear within 30–60 minutes following oral administration. MMDA produces euphoria and loving warmth, and attenuates feelings such as anxiety and loneliness. MMDA also produces eyes-closed visuals, a state of drowsiness, muscle relaxation, and time dilation. Side effects include moderate mydriasis, dizziness, sensations of heat or cold, and trembling. The imagery is generally realistic, and often related to everyday perception of people, landscapes, or objects. The effects of MMDA usually reach a peak during the first hour following the initial symptoms, and begin to wane during the second hour, and usually completely disappear by the end of the fifth hour.

Psychotherapeutic actions

In his 1973 book, The Healing Journey, Claudio Naranjo explored the psychotherapeutic potential of MMDA. Like MDA, he found that MMDA facilitates communication and suggested it has potential applications in psychotherapy. Worldwide as of 2005, MMDA has not been approved for any human applications.

Pharmacology

MMDA has been shown to act as a non-neurotoxic serotonin releasing agent with no effects on dopamine release and probably norepinephrine release as well, and as a 5-HT_2A receptor agonist. The latter property is responsible for its psychedelic effects, whereas the former mediates its mood-lifting and empathogenic effects.

Legal Status

United States

MMDA is classified as a Schedule 1 substance in the United States, and is similarly controlled in other parts of the world. Internationally, MMDA is a Schedule I drug under the Convention on Psychotropic Substances.

Australia

MMDA is considered a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.

See also

• Lophophine
• MMDA-2
• 5-Methyl-MDA
• MDA
• MDMA

External links

• PiHKAL entry for MMDA
• PiHKAL • info entry for MMDA
• MMDA: A New Psychotomimetic Agent
• Animal Pharmacology and Human Psychopharmacology of MMDA
• A Pharmacological Comparison of MMDA and LSD In The Dog